Citadel Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-207,642
| Closed | -$936K | – | 14316 |
|
|
2025
Q2 | $936K | Buy |
207,642
+53,687
| +35% | +$241K | ﹤0.01% | 7249 |
|
|
2025
Q1 | $682K | Sell |
153,955
-67,959
| -31% | -$395K | ﹤0.01% | 7795 |
|
|
2024
Q4 | $1.74M | Sell |
221,914
-52,633
| -19% | -$641K | ﹤0.01% | 5924 |
|
|
2024
Q3 | $3.61M | Buy |
274,547
+12,803
| +5% | +$162K | ﹤0.01% | 4473 |
|
|
2024
Q2 | $3.16M | Buy |
261,744
+143,443
| +121% | +$1.94M | ﹤0.01% | 4488 |
|
|
2024
Q1 | $1.92M | Sell |
118,301
-19,199
| -14% | -$259K | ﹤0.01% | 5604 |
|
|
2023
Q4 | $938K | Sell |
137,500
-276,807
| -67% | -$1.6M | ﹤0.01% | 6801 |
|
|
2023
Q3 | $2.26M | Buy |
414,307
+382,794
| +1,215% | +$2.23M | ﹤0.01% | 5006 |
|
|
2023
Q2 | $214K | Sell |
31,513
-274,197
| -90% | -$2.05M | ﹤0.01% | 9732 |
|
|
2023
Q1 | $1.53M | Sell |
305,710
-654,711
| -68% | -$2.67M | ﹤0.01% | 5874 |
|
|
2022
Q4 | $4.69M | Buy |
960,421
+869,961
| +962% | +$6.32M | ﹤0.01% | 3964 |
|
|
2022
Q3 | $1.3M | Buy |
+90,460
| New | +$1.5M | ﹤0.01% | 6436 |
|
|
2022
Q2 | – | Sell |
-26,927
| Closed | -$314K | – | 14264 |
|
|
2022
Q1 | $320K | Sell |
26,927
-98,771
| -79% | -$1.01M | ﹤0.01% | 10453 |
|
|
2021
Q4 | $2.04M | Buy |
125,698
+21,183
| +20% | +$453K | ﹤0.01% | 6186 |
|
|
2021
Q3 | $2.98M | Sell |
104,515
-70,670
| -40% | -$2.23M | ﹤0.01% | 5375 |
|
|
2021
Q2 | $5.92M | Buy |
175,185
+83,790
| +92% | +$2.69M | ﹤0.01% | 4083 |
|
|
2021
Q1 | $2.76M | Sell |
91,395
-24,074
| -21% | -$987K | ﹤0.01% | 5636 |
|
|
2020
Q4 | $5.72M | Buy |
115,469
+106,301
| +1,159% | +$4.92M | ﹤0.01% | 3470 |
|
|
2020
Q3 | $352K | Sell |
9,168
-3,832
| -29% | -$153K | ﹤0.01% | 7873 |
|
|
2020
Q2 | $561K | Sell |
13,000
-24,913
| -66% | -$942K | ﹤0.01% | 6867 |
|
|
2020
Q1 | $990K | Sell |
37,913
-32,415
| -46% | -$941K | ﹤0.01% | 5352 |
|
|
2019
Q4 | $2.2M | Buy |
+70,328
| New | +$2.08M | ﹤0.01% | 4262 |
|
Other funds holding YMAB
Citadel Advisors's YMAB Position: Q3 2025 in Review
Citadel Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 207,642 shares — an estimated $936K sold.
Citadel Advisors first reported a position in YMAB in Q4 2019 and held it in 22 quarters. The position peaked at $5.92M in Q2 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Citadel Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 207,642 Y-mAbs Therapeutics shares in Q3 2025, an estimated $936K.
- Citadel Advisors first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 22 quarters.
- Citadel Advisors's Y-mAbs Therapeutics position peaked at $5.92M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.